The effects of mirabegron used for overactive bladder treatment on female sexual function

Mirabegron and female sexual function

Authors

Keywords:

female, sexual function, overactive bladder, mirabegron

Abstract

Background/Aim: Overactive bladder (OAB) is a common condition, especially in middle-aged women and can frequently have negative effects on female sexual function (FSD). The aim of the study was to assess the impact of mirabegron on female sexual dysfunction in women affected by OAB.

Methods: In this cross-sectional study, 42 women with OAB and FSD were retrospectively enrolled. Patients were evaluated based on a detailed history, physical examination, uroflowmetry and residual urine measurements, 3-day voiding diary, visual analog scale (VAS), and Female Sexual Function Index (FSFI) questionnaire before and 12 weeks after treatment with mirabegron (50 mg/day).

Results: At the 12-week follow-up, OAB symptoms improved significantly in all patients. The mean (standard deviation [SD]) FSFI total score significantly improved in 34/42 patients (80.9%) from 16.8 (1.3) to 26.9 (1.6); P<0.001. Mean (SD) scores significantly increased in domains of desire (from 2.1 [0.6] to 4.8 [0.2]), arousal (from 2.6 [0.3] to 4.3 [0.5]), lubrication (from 3.1 [0.6] to 4,1 [0.2]), orgasm (from 3.1 [0.2] to 4.3 [0.1]), and satisfaction (from 2.8 [0.4] to 4.1 [0.5]) after 12 weeks of treatment with mirabegron. Also, mean VAS scores significantly improved from 4.4 (1.4) to 8.8 (1.1); P<0.001.

Conclusion: Treatment of OAB with mirabegron yields positive effects on sexual function of OAB patients.

Downloads

Download data is not yet available.

References

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. doi: 10.1002/nau.10052. PMID: 11857671. DOI: https://doi.org/10.1002/nau.10052

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. doi: 10.1016/j.eururo.2006.09.019. Epub 2006 Oct 2. PMID: 17049716.

Shaw C. A systematic review of the literature on the prevalence of sexual impairment in women with urinary incontinence and the prevalence of urinary leakage during sexual activity. Eur Urol. 2002 Nov;42(5):432-40. doi: 10.1016/s0302-2838(02)00401-3. PMID: 12429150. DOI: https://doi.org/10.1016/S0302-2838(02)00401-3

Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med. 2011 Jun;8(6):1603-15. doi: 10.1111/j.1743-6109.2011.02250.x. Epub 2011 Apr 14. PMID: 21492396. DOI: https://doi.org/10.1111/j.1743-6109.2011.02250.x

Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008 Jun;101(11):1388-95. doi: 10.1111/j.1464-410X.2008.07601.x. PMID: 18454794. DOI: https://doi.org/10.1111/j.1464-410X.2008.07601.x

Patel AS, O'Leary ML, Stein RJ, Leng WW, Chancellor MB, Patel SG, et al. The relationship between overactive bladder and sexual activity in women. Int Braz J Urol. 2006 Jan-Feb;32(1):77-87. doi: 10.1590/s1677-55382006000100014. PMID: 16519834. DOI: https://doi.org/10.1590/S1677-55382006000100014

Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Nov;19(11):1551-7. doi: 10.1007/s00192-008-0688-6. Epub 2008 Aug 7. PMID: 18685795. DOI: https://doi.org/10.1007/s00192-008-0688-6

Giannantoni A, Proietti S, Giusti G, Gubbiotti M, Millefiorini E, Costantini E, et al. OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results. World J Urol. 2015 Dec;33(12):2095-101. doi: 10.1007/s00345-015-1578-4. Epub 2015 May 13. PMID: 25966660. DOI: https://doi.org/10.1007/s00345-015-1578-4

Tubaro A, Batista JE, Nitti VW, Herschorn S, Chapple CR, Blauwet MB, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol. 2017 May 10;9(6):137-54. doi: 10.1177/1756287217702797. PMID: 28588652; PMCID: PMC5444577. DOI: https://doi.org/10.1177/1756287217702797

Aydin D, Aslan FE. The Turkish Adaptation Of The Female Sexual Function Index. Turkiye Klinikleri J Med Sci. 2005;25(3):393-9.

Hatzichristou D, Kirana PS, Banner L, Althof SE, Lonnee-Hoffmann RA, Dennerstein L, et al. Diagnosing Sexual Dysfunction in Men and Women: Sexual History Taking and the Role of Symptom Scales and Questionnaires. J Sex Med. 2016 Aug;13(8):1166-82. doi: 10.1016/j.jsxm.2016.05.017. PMID: 27436074. DOI: https://doi.org/10.1016/j.jsxm.2016.05.017

Zahariou A, Karamouti M, Tyligada E, Papaioannou P. Sexual function in women with overactive bladder. Female Pelvic Med Reconstr Surg. 2010 Jan;16(1):31-6. doi: 10.1097/SPV.0b013e3181bf51eb. PMID: 22453087. DOI: https://doi.org/10.1097/SPV.0b013e3181bf51eb

Miotla P, Cartwright R, Skorupska K, Bogusiewicz M, Markut-Miotla E, Futyma K, et al. Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB. Neurourol Urodyn. 2017 Aug;36(6):1564-9. doi: 10.1002/nau.23148. Epub 2016 Oct 4. PMID: 27701762. DOI: https://doi.org/10.1002/nau.23148

Duralde ER, Rowen TS. Urinary Incontinence and Associated Female Sexual Dysfunction. Sex Med Rev. 2017 Oct;5(4):470-85. doi: 10.1016/j.sxmr.2017.07.001. Epub 2017 Aug 18. PMID: 28827036. DOI: https://doi.org/10.1016/j.sxmr.2017.07.001

Su CC, Sun BY, Jiann BP. Association of urinary incontinence and sexual function in women. Int J Urol. 2015 Jan;22(1):109-13. doi: 10.1111/iju.12610. Epub 2014 Aug 29. PMID: 25170688. DOI: https://doi.org/10.1111/iju.12610

Nilsson M, Lalos O, Lindkvist H, Lalos A. How do urinary incontinence and urgency affect women's sexual life? Acta Obstet Gynecol Scand. 2011 Jun;90(6):621-8. doi: 10.1111/j.1600-0412.2011.01120.x. Epub 2011 Apr 15. PMID: 21371000. DOI: https://doi.org/10.1111/j.1600-0412.2011.01120.x

Balzarro M, Rubilotta E, Braga A, Bassi S, Processali T, Artibani W, et al. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome. Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:228-31. doi: 10.1016/j.ejogrb.2018.05.002. Epub 2018 May 5. PMID: 29753213.

Juliato CRT, Melotti IGR, Junior LCS, Britto LGO, Riccetto CLZ. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction? J Sex Med. 2017 Jul;14(7):904-9. doi: 10.1016/j.jsxm.2017.05.005. Epub 2017 Jun 15. PMID: 28622875. DOI: https://doi.org/10.1016/j.jsxm.2017.05.005

Cohen BL, Barboglio P, Gousse A. The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument. J Sex Med. 2008 Jun;5(6):1418-23. doi: 10.1111/j.1743-6109.2008.00818.x. Epub 2008 Mar 19. PMID: 18355169. DOI: https://doi.org/10.1111/j.1743-6109.2008.00818.x

Gubbiotti M, Giannantoni A, Cantaluppi S, Coluccia AC, Ghezzi F, Serati M. The impact of Mirabegron on sexual function in women with idiopathic overactive bladder. BMC Urol. 2019 Jan 21;19(1):7. doi: 10.1186/s12894-019-0438-8. PMID: 30665388; PMCID: PMC6341751. DOI: https://doi.org/10.1186/s12894-019-0438-8

Zachariou A, Filiponi M. The effect of extended release tolterodine used for overactive bladder treatment on female sexual function. Int Braz J Urol. 2017 Jul-Aug;43(4):713-20. doi: 10.1590/S1677-5538.IBJU.2016.0303. PMID: 28199076; PMCID: PMC5557448. DOI: https://doi.org/10.1590/s1677-5538.ibju.2016.0303

Balzarro M, Rubilotta E, Braga A, Bassi S, Processali T, Artibani W, et al. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome. Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:228-31. doi: 10.1016/j.ejogrb.2018.05.002. Epub 2018 May 5. PMID: 29753213. DOI: https://doi.org/10.1016/j.ejogrb.2018.05.002

Downloads

Published

2023-03-09

Issue

Section

Research Article

How to Cite

1.
Coguplugil AE, Bedir S. The effects of mirabegron used for overactive bladder treatment on female sexual function: Mirabegron and female sexual function. J Surg Med [Internet]. 2023 Mar. 9 [cited 2024 Jun. 23];7(3):205-8. Available from: https://jsurgmed.com/article/view/7733